Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons within the substantia nigra, leading to the hallmark motor and non-motor symptoms. While current treatments predominantly offer symptomatic relief, halting disease progression remains elusive. The study conducted by Camacho-Meño, Labandeira, Bravo, and colleagues breaks new ground by targeting neuroprotection at a molecular signaling level facilitated through brain-derived extracellular vesicles, a relatively untapped reservoir of intercellular communication and biomarkers.

Extracellular vesicles—nano-sized, membrane-bound particles released by cells—carry proteins, lipids, and nucleic acids, conveying physiological and pathological information between neurons and glia. Their proteomic profiling offers unparalleled insight into cellular states and systemic interventions. In this study, the authors harvested brain tissue samples from Parkinson’s patients treated with candesartan and employed state-of-the-art mass spectrometry to dissect the proteome encapsulated within these vesicles, revealing significant alterations associated with neuronal survival pathways.

Central to their findings is the modulation of neuroinflammation and oxidative stress responses by candesartan. The ARB appeared to recalibrate the brain’s microenvironment by suppressing pro-inflammatory signaling cascades within the extracellular vesicles while simultaneously augmenting antioxidant defenses. This dual modulation potentially interrupts the vicious cycle of inflammation-induced neuronal damage that accelerates PD progression, a pathological hallmark previously difficult to address pharmacologically.

Furthermore, proteomic signatures from candesartan-treated patients highlighted upregulation of proteins involved in mitochondrial function and synaptic plasticity. The enhancement of mitochondrial bioenergetics is particularly critical, given that mitochondrial dysfunction is a key contributor to dopaminergic neuronal demise in Parkinson’s disease. By preserving mitochondrial integrity through EV-mediated protein transfer, candesartan may bolster neuronal resilience in the neurodegenerative milieu.

Interestingly, the study also uncovered biomarkers predictive of treatment responsiveness embedded within the EV proteome, hinting at the possibility of personalized therapeutic monitoring. This precision medicine angle underscores the importance of extracellular vesicles not only as therapeutic effectors but also as diagnostic tools, enabling clinicians to tailor interventions based on individual proteomic landscapes.

The implications of these findings extend beyond Parkinson’s disease, offering a novel framework for understanding how ARBs, traditionally employed for cardiovascular conditions, can exert repurposed benefits in neurodegeneration. Candesartan’s capacity to traverse the blood-brain barrier and modulate brain-specific molecular pathways within EVs underscores a paradigm shift in neurotherapeutics, harmonizing systemic drug delivery with localized neuronal protection.

Methodologically, the research team employed rigorous controls and advanced quantitative proteomics techniques, ensuring reproducibility and robustness in their results. The application of tandem mass tag (TMT) labeling permitted high-throughput, multiplexed profiling with precise quantification across patient cohorts, enhancing the granularity of comparative analyses between treated and untreated groups.

Moreover, this study navigates the complexity of EV heterogeneity by differentiating vesicle subtypes through size exclusion chromatography and immunoaffinity capture, refining the specificity of proteomic data. Such meticulous separation enables attribution of neuroprotective signatures to distinct vesicle populations, a crucial step toward targeted therapeutic development.

The translational potential of this research is immense. By validating candesartan’s neuroprotection via brain-derived EVs, the findings advocate for clinical trials assessing its efficacy in slowing PD progression, heralding an era where angiotensin system modulation could become a cornerstone of Parkinson’s management. This repurposing also promises expedited availability, given candesartan’s established safety profile and widespread clinical use in hypertension.

Critically, the study also prompts a reevaluation of PD’s pathophysiological frameworks, emphasizing intercellular communication via extracellular vesicles as pivotal in disease dynamics and intervention. It encourages expanded explorations into how other pharmacological agents influence EV cargo and function, potentially unearthing new therapeutic avenues.

In conclusion, this pioneering investigation not only fortifies candesartan’s candidacy as a neuroprotective agent but also elevates brain-derived extracellular vesicle proteomics as a transformative tool in neurodegenerative disease research. The convergence of proteomics, nanotechnology, and pharmacology in this context provides a blueprint for future studies aimed at deciphering the molecular underpinnings of brain health and disease.

As Parkinson’s disease continues to challenge medical science, the integration of advanced proteomic methodologies with drug repurposing strategies offers a beacon of hope. By unraveling the molecular dialogue conveyed through brain-derived EVs, researchers are charting a course toward targeted, mechanism-based therapies that could preserve neuronal function and transform patient outcomes.

Future directions inspired by this research will likely involve longitudinal studies tracking EV proteomic changes throughout disease progression under candesartan treatment, exploring synergistic effects with other neuroprotective compounds, and expanding investigations into other neurodegenerative disorders characterized by distinct EV signatures.

This influential work thus represents a milestone in PD therapeutics, merging molecular precision with clinical pragmatism. As the scientific community delves deeper into extracellular vesicle biology, it paves the way for innovative treatments that harness the body’s own intercellular messaging system to combat neurodegeneration.

Subject of Research: Neuroprotective effects of the angiotensin receptor blocker candesartan in Parkinson’s disease patients, analyzed through proteomic profiling of brain-derived extracellular vesicles.

Article Title: Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson’s disease patients.

Article References:
Camacho-Meño, L., Labandeira, C.M., Bravo, S.B. et al. Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson’s disease patients. npj Parkinsons Dis. (2025). https://doi.org/10.1038/s41531-025-01230-6

Image Credits: AI Generated

The study demonstrates for the first time that lithium is naturally present in the human brain at physiologically significant levels. More importantly, this trace metal diminishes markedly early in Alzheimer’s disease progression. Lithium’s neuroprotective properties appear multifaceted, sustaining the normal function of neurons and glial cells while mitigating pathological cascades that lead to synaptic loss, neuroinflammation, and cognitive impairment. The researchers integrated advanced mass spectrometry techniques to accurately quantify lithium alongside other metals in postmortem brain samples, spanning cognitively healthy individuals to those experiencing severe dementia. This comprehensive approach confirmed that among approximately 30 metals studied, lithium distinctly decreases at the initial stages of cognitive decline.

Mechanistic investigations in genetically engineered mouse models of Alzheimer’s disease recapitulated the human findings, revealing that dietary lithium restriction accelerates pathological features synonymous with Alzheimer’s, including amyloid-beta accumulation and tau pathology. Intriguingly, lithium depletion activated brain immune cells, microglia, in ways that impaired their ability to clear amyloid deposits — a known contributor to disease progression. Lithium-deficient mice also displayed exacerbated synapse and axon loss alongside widespread myelin degradation, cellular events that collectively derail neural circuitry essential for memory and cognition.

One of the most compelling aspects of the research is the elucidation of how pathological amyloid beta plaques perturb lithium homeostasis. Lithium ions are sequestered by amyloid aggregates, effectively reducing their bioavailability and diminishing lithium’s normal physiological roles. This sequestration explains not only the depletion observed but also why previous attempts to treat Alzheimer’s with high doses of standard lithium salts, such as lithium carbonate, yielded limited success and toxicity concerns: common lithium formulations can be trapped by plaques before exerting neuroprotective effects.

To circumvent this challenge, the research team developed and screened a new class of lithium-based compounds designed to evade amyloid binding. Lithium orotate emerged as a leading candidate, effectively restoring lithium levels in the brain without being captured by amyloid beta. Remarkably, oral administration of lithium orotate at doses much lower than those used clinically for psychiatric conditions reversed Alzheimer’s pathology and rescued memory function in aged mice. The compound’s efficacy at such low dosage levels significantly minimizes toxicity risks and holds promise for safe, long-term therapeutic use.

At the molecular level, lithium influenced gene expression networks linked to Alzheimer’s risk, including the well-studied APOE gene — a major genetic determinant in disease susceptibility. This genomic modulation points to lithium’s broad regulatory capacity, suggesting it supports brain resilience not just by counteracting known pathological proteins but by maintaining homeostatic gene expression critical to neural health.

The translational implications of these findings are profound. Current clinical strategies that target amyloid beta alone have failed to halt or reverse cognitive decline sufficiently. Lithium-based treatment introduces a broader neuroprotective strategy aimed at preserving overall brain function and cellular health. Furthermore, routine lithium level screening through blood tests could pave the way for earlier diagnosis and stratification of patients who may benefit most from lithium supplementation or novel lithium derivatives.

Cautious optimism permeates the research community, with the senior author, Dr. Bruce Yankner, emphasizing that clinical validation is vital before widespread adoption. Nonetheless, he notes that the extensive neuroprotective effects observed in murine models, coupled with the identification of amyloid-evading lithium compounds, mark a paradigm shift in Alzheimer’s research. Importantly, long-term administration of lithium orotate in mice did not produce toxicity, contrasting sharply with the often adverse effects reported using traditional lithium therapies.

The study also interfaces with epidemiological observations that regions with higher environmental lithium exposure through drinking water tend to have lower dementia prevalence, thereby reinforcing a biological basis for lithium’s protective role. This blend of observational data, human postmortem analyses, and mechanistic animal studies provides an unprecedented multidimensional picture of lithium’s essentiality in brain aging and neurodegeneration.

While questions remain—such as optimal dosing, long-term safety in humans, and whether lithium therapy can truly reverse advanced disease—the research charts a promising course for novel interventions targeting early pathophysiological changes before overt clinical decline. This work represents a major stepping stone toward slowing, preventing, or potentially reversing Alzheimer’s disease by addressing a previously neglected but critical element: lithium homeostasis.

The discovery also broadens our understanding of Alzheimer’s heterogeneity, explicating why diverse outcomes occur among individuals with similar neuropathology. Variability in brain lithium levels and handling could underlie differential resistance or vulnerability, offering a personalized medicine perspective to future therapeutics.

As the global burden of Alzheimer’s continues to escalate with aging populations, these findings underscore an urgent need to rethink disease models and embrace integrative strategies incorporating trace elements like lithium. Pending rigorous clinical trials, lithium orotate and related compounds may soon emerge as viable options in the fight against cognitive decline, fulfilling the long-standing quest for effective Alzheimer’s interventions addressing the disease’s underlying biology holistically.

Subject of Research: Human tissue samples

Article Title: Lithium deficiency and the onset of Alzheimer’s disease

News Publication Date: 6-Aug-2025

Web References:

• https://www.nature.com/articles/s41586-025-09335-x
• https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12694
• https://yankner.hms.harvard.edu/
• https://www.rushu.rush.edu/research-rush-university/departmental-research/rush-alzheimers-disease-center

References:
Yankner et al., Nature, 2025, DOI: 10.1038/s41586-025-09335-x

Image Credits: Yankner Lab

Keywords: Alzheimer disease, Neurodegenerative diseases, Dementia, Genetics, Human genetics, Older adults, Aging populations, Cognitive disorders, Mouse models, Brain tissue, Human health, Diseases and disorders